Assessing cognitive trajectories in Progressive Supranuclear Palsy using remote computerized reaction time tasks (Trial Not Registered)
Cognition in Progressive Supranuclear Palsy
This study aims to assess the potential role for remote computerised cognitive battery measurements in detecting short-term cognitive decline in PSP, and to explore its role as a novel biomarker for disease progression in descriptive and therapeutic clinical trials.
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Other
Trial participation type
This trial has been designed for the Clinical Research of a Device.
Principal investigator
Dr Kelly Bertram
Key inclusion data
Inclusion: Participants aged 40 or over with a diagnosis of PSP according to the 2017 MDS criteria made by a Neurologist; Registered study participant of the Alfred Neurology BioData bank (Alfred HREC 157/19) and consenting to data and material sharing; Current right of access to Medicare as per Commonwealth and Victorian State government policy.
Exclusion: Significant neurological or neuropsychiatric diagnosis deemed to interfere with cognitive or other testing (e.g., Alzheimer’s disease, schizophrenia etc); Unable to complete study protocol procedures (e.g., severely disabling disease, non-English speaking, geographical location, no access to suitable device for CCB completion, no access to internet connection).
If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.